Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of “Hold” by Analysts

Nektar Therapeutics (NASDAQ:NKTR) has received an average rating of “Hold” from the five analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $3.50.

NKTR has been the subject of a number of research analyst reports. Jefferies Financial Group raised their target price on Nektar Therapeutics from $0.50 to $1.00 and gave the company a “hold” rating in a research note on Wednesday, March 6th. StockNews.com began coverage on Nektar Therapeutics in a research note on Friday, January 26th. They set a “hold” rating for the company. Finally, William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a research note on Tuesday, March 5th.

Institutional Trading of Nektar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of NKTR. RA Capital Management L.P. bought a new stake in shares of Nektar Therapeutics in the 3rd quarter worth $11,138,000. GSA Capital Partners LLP lifted its holdings in shares of Nektar Therapeutics by 185.5% in the fourth quarter. GSA Capital Partners LLP now owns 5,255,790 shares of the biopharmaceutical company’s stock worth $2,970,000 after buying an additional 3,414,712 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of Nektar Therapeutics by 73.5% during the third quarter. Acadian Asset Management LLC now owns 7,626,388 shares of the biopharmaceutical company’s stock valued at $4,540,000 after purchasing an additional 3,230,368 shares in the last quarter. Lynx1 Capital Management LP purchased a new position in shares of Nektar Therapeutics during the third quarter valued at about $1,052,000. Finally, Monaco Asset Management SAM lifted its holdings in shares of Nektar Therapeutics by 24.2% in the 4th quarter. Monaco Asset Management SAM now owns 5,973,387 shares of the biopharmaceutical company’s stock valued at $3,375,000 after acquiring an additional 1,163,786 shares during the last quarter. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Stock Up 4.4 %

NKTR opened at $1.42 on Wednesday. The stock has a market cap of $260.74 million, a PE ratio of -0.97 and a beta of 0.90. The business has a 50 day moving average of $0.99 and a 200-day moving average of $0.69. Nektar Therapeutics has a 52 week low of $0.41 and a 52 week high of $1.75.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Monday, March 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.01). The firm had revenue of $23.89 million during the quarter, compared to analysts’ expectations of $17.09 million. Nektar Therapeutics had a negative net margin of 306.31% and a negative return on equity of 96.80%. During the same quarter in the previous year, the business earned ($0.32) EPS. Equities analysts anticipate that Nektar Therapeutics will post -0.93 EPS for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer.